Program
sotatercept
Also written as “Sotatercept”, “Sotatercept 0.3 mg/kg” and “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”.
Its studies are mostly in Pulmonary Arterial Hypertension · Anemia · Hypertension, Pulmonary · Multiple Myeloma · beta-Thalassemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 228 open or running | phase 4since May 15, 2026 | May 22, 2009 | Mar 21, 2028phase 4 · NCT07899905 |
| Bristol-Myers Squibb | 40 open or running | phase 2since Sep 3, 2008 | Sep 3, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Sep 3, 2008.
- May 13, 2021Phase 3 study in Pulmonary Arterial HypertensionMerck · NCT04896008 · 173 enrolled · United States, Australia, Belgium and more
- Jun 11, 2021Phase 2 study in Hypertension, PulmonaryMerck · NCT04945460 · 165 enrolled · United States, Belgium, Canada and more
- Oct 17, 2022Phase 2 study in Pulmonary Arterial HypertensionMerck · NCT05587712 · 42 planned · United States, Australia, Colombia and more
- Apr 5, 2023Phase 3 study in Pulmonary Arterial HypertensionMerck · NCT05818137 · 46 enrolled · Japan
- Oct 28, 2024Phase 2 study in Pulmonary Arterial HypertensionMerck · NCT06664801 · 164 enrolled · United States, Argentina, Australia and more
- Feb 3, 2025Phase 2 study in Hypertension, PulmonaryMerck · NCT06814145 · 440 enrolled · United States, Belgium, Canada and more
- Feb 20, 2025Phase 1 study in HealthyMerck · NCT06843460 · 24 enrolled · China
- Apr 7, 2025Phase 2 study in Pulmonary Arterial HypertensionMerck · NCT06925750 · 130 enrolled · United States, Argentina, Australia and more
- Apr 9, 2025Phase 1 study in HealthyMerck · NCT06930664 · 146 enrolled · United States
- Oct 7, 2025Phase 3 study in Pulmonary Arterial HypertensionMerck · NCT07218029 · 815 enrolled · United States, Argentina, Australia and more
- May 15, 2026Phase 4 study in Pulmonary Arterial HypertensionMerck · NCT07600723 · 30 planned · India
- Jun 9, 2026Phase 2 study in Pulmonary Arterial HypertensionMerck · NCT07646860 · 6 planned · Japan
- Sep 18, 2026Phase 3 study in Hypertension, PulmonaryMerck · NCT07839585 · 352 planned
- Oct 21, 2026Phase 4 study in Hypertension, PulmonaryMerck · NCT07899905 · 40 planned
Ahead
- Mar 21, 2028Primary completion: phase 4 study in Hypertension, PulmonaryMerck · NCT07899905
- Apr 3, 2028Primary completion: phase 4 study in Pulmonary Arterial HypertensionMerck · NCT07600723
- Jun 16, 2028Primary completion: phase 2 study in Pulmonary Arterial HypertensionMerck · NCT06925750
- Sep 21, 2028Primary completion: phase 2 study in Pulmonary Arterial HypertensionMerck · NCT05587712
TargetBeta
“Inhibin beta A chain inhibitor”ChEMBL 37, by rule
Other programs on INHBA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| garetosmabrule | Regeneron Pharmaceuticals | phase 3 | 9 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07899905Hypertension, Pulmonary | 4 | Not yet recruiting | Merck | Mar 21, 2028 | 40 |
| NCT07839585Hypertension, Pulmonary | 3 | Not yet recruiting | Merck | Jan 8, 2030 | 352 |
| NCT07646860Pulmonary Arterial Hypertension · Japan | 2 | Recruiting | Merck | May 24, 2029 | 6 |
| NCT07600723Pulmonary Arterial Hypertension · India | 4 | Recruiting | Merck | Apr 3, 2028 | 30 |
| NCT07218029Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Dec 7, 2028 | 815 |
| NCT06930664Healthy · United States | 1 | Completed | Merck | Nov 11, 2025 | 146 |
| NCT06925750Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 2 | Active, not recruiting | Merck | Jun 16, 2028 | 130 |
| NCT06843460Healthy · China | 1 | Completed | Merck | May 21, 2024 | 24 |
| NCT06814145Hypertension, Pulmonary · United States, Belgium, Canada and more | 2 | Active, not recruiting | Merck | Aug 10, 2035 | 440 |
| NCT06664801Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 2 | Completed | Merck | Nov 20, 2025 | 164 |
| NCT05818137Pulmonary Arterial Hypertension · Japan | 3 | Completed | Merck | Mar 12, 2024 | 46 |
| NCT05587712Pulmonary Arterial Hypertension · United States, Australia, Colombia and more | 2 | Recruiting | Merck | Sep 21, 2028 | 42 |
| NCT04945460Hypertension, Pulmonary · United States, Belgium, Canada and more | 2 | Completed | Merck | Sep 5, 2025 | 165 |
| NCT04896008Pulmonary Arterial Hypertension · United States, Australia, Belgium and more | 3 | Completed | Merck | Jul 26, 2024 | 173 |
| NCT04811092Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Terminated | Merck | Apr 3, 2025 | 321 |
| NCT04576988Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | Merck | Aug 26, 2022 | 324 |
| NCT03738150Pulmonary Arterial Hypertension · United States | 2 | Completed | Merck | Dec 21, 2021 | 21 |
| NCT03496207Pulmonary Arterial Hypertension · United States, Australia, Brazil and more | 2 | Completed | Merck | Mar 9, 2022 | 106 |
| NCT01999582Anemia · Belgium, Germany, Portugal and more | 2 | Completed | Bristol-Myers Squibb | Aug 31, 2016 | 50 |
| NCT01736683Anemia · United States, France | 2 | Completed | Merck | Apr 30, 2018 | 74 |
| NCT01571635beta-Thalassemia · France, Greece, Italy and more | 2 | Terminated | Bristol-Myers Squibb | Jul 2, 2015 | 46 |
| NCT01284348Anemia | 2 | Terminated | Merck | Sep 21, 2012 | 26 |
| NCT01190644Solid Tumors · United States | 2 | Terminated | Merck | Sep 18, 2012 | 5 |
| NCT01146574Anemia · United States | 2 | Completed | Bristol-Myers Squibb | Mar 7, 2016 | 50 |
| NCT00931606Anemia · United States, Russian Federation | 2 | Terminated | Merck | Nov 18, 2010 | 30 |
| NCT00747123Multiple Myeloma · Russian Federation | 2 | Completed | Bristol-Myers Squibb | Aug 1, 2009 | 30 |
How it is read
Names in the registry
- “Sotatercept”, 22 entries
- “Sotatercept 0.3 mg/kg”, 1 entry
- “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”, 1 entry
- “Sotatercept Autoinjector”, 1 entry
- “ACE-011”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 12 studies
- Anemia, 5 studies
- Hypertension, Pulmonary, 4 studies
- Multiple Myeloma, 1 study
- beta-Thalassemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.